1
|
Liu Z, Tong Y, Wu J, Du L, Wei C, Cui W, Cao Y, Chen M, Cai Z, Chen W, Ding H, Guan M, Guo W, Gao C, Hao X, Hu C, Huang S, Jiang Y, Li J, Li P, Li Z, Ming L, Pan S, Shen Z, Su J, Sun Z, Wang H, Wang J, Xu B, Yu N, Zheng L, Zhang Y, Zhang X, Zhang Y, Duan Y, Wang C. Chinese Expert Consensus on the Nucleic Acid Detection of SARS-CoV-2. ANNALS OF TRANSLATIONAL MEDICINE 2020; 8:1631. [PMID: 33490143 PMCID: PMC7812184 DOI: 10.21037/atm-20-4060] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The coronavirus disease 2019 (COVID-19) has already become a pandemic wherein the infection's timely diagnosis has proven beneficial to patient treatment and disease control. Nucleic acid detection has been the primary laboratory diagnostic method for the detection of SARS-CoV-2. To ensure laboratory staff safety and quality nucleic acid testing, the Chinese Society of Laboratory Medicine formulated this consensus, based on the Chinese National Recommendations and previous literature for nucleic acid detection. A working group comprises 34 hospital professionals experience with real-time polymerase chain reactions (PCR) testing for SARS-CoV-2 drafted guidance statements during online discussions. A modified Delphi methodology was used in forming a consensus among a wider group of hospital professionals with SARS-CoV-2 detection experience. Guidance statements were developed for four categories: (I) specimen type, priority, collecting, transportation and receiving; (II) nucleic acid isolation and amplification; (III) quality control; (IV) biosafety management and decontamination. The modified Delphi voting process included a total of 29 guidance statements and final agreement. Consensus was reached after two rounds of voting. Recommendations were established for the detection of SARS-CoV-2 using real time PCR testing based on evidence and group consensus. The manuscript was evaluated against The Appraisal of Guidelines for Research & Evaluation Instrument (AGREE II) and was developed to aid medical laboratory staff in the detection of the ribonucleic acid (RNA) of SARS-CoV-2.
Collapse
Affiliation(s)
- Zijie Liu
- Yunnan Key Laboratory of Laboratory Medicine, Kunming, China.,Department of Laboratory Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Yongqing Tong
- Laboratory Medicine Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Jun Wu
- Department of Clinical Laboratory, Shanghai General Hospital Jiading Branch, Shanghai, China
| | - Lutao Du
- Laboratory Medicine Center of The Second Hospital of Shandong University, Jinan, China
| | - Chaojun Wei
- The Institute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, Lanzhou, China
| | - Wei Cui
- Department of Laboratory Medicine, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - Yongtong Cao
- Laboratory Department of China-Japan Friendship Hospital, Beijing, China
| | - Ming Chen
- Laboratory Department of Southwest Hospital, Chongqing, China
| | - Zhen Cai
- Department of Laboratory Medicine, Nanfang Hospital of Southern Medical University, Guangzhou, China
| | - Wei Chen
- Department of Laboratory Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Haitao Ding
- Department of Laboratory Medicine, People's Hospital of Inner Mongolia Autonomous Region, Hohhot, China
| | - Ming Guan
- Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Wei Guo
- Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Chunfang Gao
- Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
| | - Xiaoke Hao
- Department of Laboratory Medicine, Xijing Hospital, Air Force Military Medical University, Xi'an, China
| | - Chengjin Hu
- Department of Laboratory Diagnosis, 960th Hospital of Chinese PLA, Jinan, China
| | - Shan Huang
- Guizhou Province Center for Clinical Laboratory, Guiyang, China
| | - Yanfang Jiang
- Gene Diagnostic Center of the First Hospital of Jilin University, Changchun, China
| | - Jinming Li
- National Center for Clinical Laboratories, Beijing, China
| | - Ping Li
- Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, China
| | - Zhuo Li
- Department of Laboratory Medicine, the First Affiliated Hospital of Xi'an Medical College, Xian, China
| | - Liang Ming
- Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Shiyang Pan
- Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Zuojun Shen
- Scientific Research Department of the First Affiliated Hospital of University of Science and Technology of China, Hefei, China
| | - Jianrong Su
- Department of Laboratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Ziyong Sun
- Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Hui Wang
- Department of Laboratory Medicine, Peking University People's Hospital, Beijing, China
| | - Junjun Wang
- Department of Laboratory Medicine, Eastern Theater General Hospital; Nanjing, China
| | - Bin Xu
- Provincial Clinical Inspection Center of Jiangsu Cancer Hospital, Nanjing, China
| | - Nong Yu
- Laboratory of Suzhou Branch of Xinhua Hospital Affiliated to Shanghai Jiaotong University, Suzhou, China
| | - Lei Zheng
- Department of Laboratory Medicine, Nanfang Hospital of Southern Medical University, Guangzhou, China
| | - Yi Zhang
- Department of Laboratory Medicine, Qilu Hospital of Shandong University, Jinan, China
| | - Xin Zhang
- Department of Laboratory Medicine of Xinjiang Production and Construction Corps Hospital, Urumqi, China
| | - Ying Zhang
- Department of Clinical Laboratory Medicine, the First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Yong Duan
- Yunnan Key Laboratory of Laboratory Medicine, Kunming, China.,Department of Laboratory Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Chengbin Wang
- Department of Clinical Laboratory Medicine, the First Medical Center, Chinese PLA General Hospital, Beijing, China
| |
Collapse
|
3
|
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011; 24:314-50. [PMID: 21482728 DOI: 10.1128/cmr.00059-10] [Citation(s) in RCA: 311] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
With an estimated 9.4 million new cases globally, tuberculosis (TB) continues to be a major public health concern. Eighty percent of all cases worldwide occur in 22 high-burden, mainly resource-poor settings. This devastating impact of tuberculosis on vulnerable populations is also driven by its deadly synergy with HIV. Therefore, building capacity and enhancing universal access to rapid and accurate laboratory diagnostics are necessary to control TB and HIV-TB coinfections in resource-limited countries. The present review describes several new and established methods as well as the issues and challenges associated with implementing quality tuberculosis laboratory services in such countries. Recently, the WHO has endorsed some of these novel methods, and they have been made available at discounted prices for procurement by the public health sector of high-burden countries. In addition, international and national laboratory partners and donors are currently evaluating other new diagnostics that will allow further and more rapid testing in point-of-care settings. While some techniques are simple, others have complex requirements, and therefore, it is important to carefully determine how to link these new tests and incorporate them within a country's national diagnostic algorithm. Finally, the successful implementation of these methods is dependent on key partnerships in the international laboratory community and ensuring that adequate quality assurance programs are inherent in each country's laboratory network.
Collapse
|
4
|
[Utility of molecular biology in the microbiological diagnosis of mycobacterial infections]. Enferm Infecc Microbiol Clin 2009; 26 Suppl 9:33-41. [PMID: 19195445 DOI: 10.1016/s0213-005x(08)76539-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Species within the Mycobacterium genus are of major medical interest, since, together with environmental and opportunistic species, there are two species (Mycobacterium tuberculosis and Mycobacterium leprae) that remain an important public health challenge. Despite efforts to control tuberculosis (TB), this disease remains one of the most prominent health problems worldwide. In the last few years, mycobacteriology has experienced major technological advances. Nevertheless, the early diagnosis of mycobacterial infection and, especially of TB, is still based on microscopic examination of properly stained samples. At present, this procedure is still the simplest, fastest and most cost-effective method for preliminary diagnostic guidance. Effective control of TB is based on rapid detection of M. tuberculosis, followed by immediate implementation of the appropriate antituberculosis therapy. Because of the emergence of multidrug resistant strains, the development of rapid diagnostic methods, both for identification of M. tuberculosis and susceptibility testing, has become a pressing need. The availability of molecular epidemiology methods that are easy to implement and standardized and that would allow identification of related cases is of key importance to identify epidemic outbreaks and control the spread of TB. Despite the evident progress in the molecular diagnosis of mycobacterial infections, the available techniques are still inadequate. In this review, we describe the state of the art of the main molecular techniques for direct detection of mycobacteria in clinical samples, their identification, detection of resistance to the most important antituberculosis agents, and molecular epidemiology. In each case, we describe the advantages and limitations of current techniques. In the near future, clinical mycobacteriology will probably evolve to the universal use of genetic techniques for direct diagnosis and detection of resistance. The molecular epidemiology of TB will be performed, in its various applications, by faster and more automated techniques than those currently available.
Collapse
|